Increased Incidence of Ischemic Cerebrovascular Events in Cardiovascular Patients With Elevated Apolipoprotein CIII
Open Access
- 1 January 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 51 (1) , 61-68
Abstract
Background and Purpose—: Apo CIII (apolipoprotein CIII), a crucial regulator of lipoprotein metabolism, has been associated with increased activity of coagulation factors and thrombin generation and, in turn, with an increased risk of thromboembolic events in both arterial and venous districts. Thus, we hypothesized that it may affect the risk of acute ischemic cerebrovascular events in cardiovascular patients. Methods—: We systematically checked medical records and quantified cerebral ischemic events in a cohort of 950 subjects (median age 65 with interquartile range, 55–79 years; 30.7% females) with or without angiographically defined coronary artery disease (CAD: 774 CAD and 176 CAD-free, respectively). All the subjects, enrolled between May 1999 and December 2006, were prospectively followed until death or July 31, 2018. Assessments of complete plasma lipid and apolipoprotein profiles, including Apo A-I, B, CIII, and E, were available for all subjects at enrollment. Results—: After a median follow-up of 130 months (interquartile range, 69–189), 95 subjects (10%) suffered ischemic stroke/transient ischemic attack (TIA) events. Stroke/TIA subjects had higher Apo CIII plasma concentration (11.4; interquartile range: 9.3–14.4 mg/dL) at enrollment than those without stroke/TIA (10.4, interquartile range: 8.7–13.0 mg/dL). Subjects with Apo CIII levels above the median value (10.6 mg/dL) exhibited an ≈2-fold increased risk of stroke/TIA, even after adjustment for potential confounders, including sex, age, CAD diagnosis, hypertension, atrial fibrillation, oral anticoagulant treatment, and all plasma lipid parameters (hazard ratio: 2.23 [95% CI, 1.21–4.13]). This result was confirmed in CAD and CAD-free populations, separately, and even by a propensity score matching method, in which 98 CAD and 98 CAD-free subjects were one-to-one matched for all clinical and laboratory characteristics. Conclusions—: These findings suggest that a high Apo CIII plasma concentration may predict an increased risk of ischemic stroke/TIA in cardiovascular patients.Keywords
This publication has 31 references indexed in Scilit:
- Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A AlleleJournal of the American Heart Association, 2013
- Heart Disease and Stroke Statistics—2011 UpdateCirculation, 2011
- Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke SubtypesStroke, 2009
- Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid AtherosclerosisStroke, 2008
- Importancia del perfil cardiovascular en la mortalidad hospitalaria de los infartos cerebralesRevista Espanola de Cardiologia, 2008
- Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and WomenStroke, 2008
- Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell DysfunctionCirculation, 2008
- Apolipoprotein C-III: understanding an emerging cardiovascular risk factorClinical Science, 2008
- An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?International Journal Of Clinical Practice, 2008
- Matched Case-Control Study on Factor V Leiden and the Prothrombin G20210A Mutation in Patients With Ischemic Stroke/Transient Ischemic Attack Up to the Age of 60 YearsStroke, 2005